暂无数据
产品名称
起订量
单价(含增值税)
库存(PCS)
起订数量
产品简介
英文名称 | Anti-IKZF1 Polyclonal Antibody |
别名 | CVID13;Hs.54452;IK1;IKAROS;LYF1;LyF-1;PPP1R92;PRO0758;ZNFN1A1 |
宿主 | Rabbit |
稀释比例 | WB 1:500-2000. IHC 1:50-200. IF 1:50-200. |
Gene ID | 10320 |
保存 | Store at -20°C. Avoid freeze / thaw cycles. |
Swiss Prot | Q13422 |
蛋白分子量 | 58kDa |
储存液 | Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3. |
亚细胞定位 | Cytoplasm Nucleus Nucleus |
免疫原 | Recombinant protein of human IKZF1 |
亚型 | IgG |
性状 | 液体 |
纯化方法 | Affinity purification |
背景资料 | This gene encodes a transcription factor that belongs to the family of zinc-finger DNA-binding proteins associated with chromatin remodeling. The expression of this protein is restricted to the fetal and adult hemo-lymphopoietic system, and it functions as a regulator of lymphocyte differentiation. Several alternatively spliced transcript variants encoding different isoforms have been described for this gene. Most isoforms share a common C-terminal domain, which contains two zinc finger motifs that are required for hetero- or homo-dimerization, and for interactions with other proteins. The isoforms, however, differ in the number of N-terminal zinc finger motifs that bind DNA and in nuclear localization signal presence, resulting in members with and without DNA-binding properties. Only a few isoforms contain the requisite three or more N-terminal zinc motifs that confer high affinity binding to a specific core DNA sequence element in the promoters of target genes. The non-DNA-binding isoforms are largely found in the cytoplasm, and are thought to function as dominant-negative factors. Overexpression of some dominant-negative isoforms have been associated with B-cell malignancies, such as acute lymphoblastic leukemia (ALL). |
Public Immunogen Range | Recombinant protein of human IKZF1 |
克隆类型 | Polyclonal Antibody |
交叉反应 | HumanRatMouse |
应用 | WBIF |
规格 | 50ul100ul |
注意:
1.本产品仅供科研使用。请勿用于医药、临床诊断或治疗,食品及化妆品等用途。请勿存放于普通住宅区。
2.为了您的安全和健康,请穿好实验服并佩戴一次性手套和口罩操作。
暂无数据
我要询价
*联系方式:
(可以是QQ、MSN、电子邮箱、电话等,您的联系方式不会被公开)
*内容: